January round-up of pharmaceutical & biotech M&A activity

1 February 2018
mergers-acquisitions-big

Companies have not spent long sitting on cash piles freed up by the long-awaited US tax reforms after they were approved by the Senate last month.

The Financial Times  called it pharma’s strongest start to mergers and acquisitions (M&A) for a decade, and if January is a sign of things to come, it could be an unprecedented year of deals in the sector.

Around $30 billion has been spent over the month, with French pharma major Sanofi (Euronext: SAN) and US biotech Celgene (Nasdaq: CELG) among the biggest spenders.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical